Right ventricular arrhythmias

Der Internist
Thomas WichterGünter Breithardt

Abstract

Right ventricular arrhythmias predominantly occur in young patients with rare cardiac diseases. Underlying cardiac conditions include idiopathic right ventricular outflow-tract tachycardia (RVOT-VT), arrhythmogenic right ventricular cardiomyopathy (ARVC), Brugada syndrome, and postoperative congenital heart disease (i.e. tetralogy of Fallot). According to the underlying cardiac disease, there are significant differences in the diagnostic and therapeutic management and prognosis which is mainly determined by life-threatening ventricular arrhythmia recurrences and sudden cardiac death. To provide optimal treatment for affected patients, a detailed diagnostic evaluation and risk stratification is mandatory. Tailored treatment strategies aim at the suppression or effective termination of recurrent ventricular tachyarrhythmias and prevention of sudden death by antiarrhythmic drug therapy, catheter ablation, and the implantation of cardioverter-defibrillators. This review summarizes the current knowledge on pathogenesis, diagnosis, treatment and prognosis of those conditions that are associated with arrhythmias originating from the right ventricle.

References

Jan 21, 1988·The New England Journal of Medicine·G ThieneN Pennelli
Feb 1, 1982·Circulation·F I MarcusY Grosgogeat
May 22, 1998·Medizinische Klinik·T WichterG Breithardt
Oct 12, 1999·Journal of Cardiovascular Electrophysiology·J P Saul, M E Alexander
Mar 10, 2001·Journal of Cardiovascular Electrophysiology·C Antzelevitch
May 2, 2002·Cardiac Electrophysiology Review·Bruce B LermanDavid J Slotwiner
Jun 28, 2002·Cardiovascular Drugs and Therapy·Josep BrugadaRamon Brugada
Nov 6, 2002·Circulation·Arthur A M WildeUNKNOWN Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology
Nov 20, 2002·Cardiac Electrophysiology Review·Christopher R ColeAndrea Natale
Feb 8, 2003·Herz·Thomas WichterGünter Breithardt
Jul 10, 2003·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Pietro TurriniGaetano Thiene

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Arrhythmogenic Right Ventricular Dysplasia

Arrhythmogenic right ventricular dysplasia is a congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the right ventricle wall and loss of myocardial cells. Primary injuries usually are at the free wall of the right ventricular and right atria resulting in ventricular and supraventricular arrhythmias. Discover the latest research on arrhythmogenic right ventricular dysplasia here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.